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ABSTRACT
Purpose To evaluate the potential of fluorescence single
particle tracking (fSPT) for the characterization of submicron
protein aggregates in human serum, plasma and formulations
containing human serum albumin (HSA).
Methods A monoclonal IgG was covalently labeled with a
fluorescent dye and cross-linked with glutaraldehyde. IgG
aggregates and fluorescent beads of 0.1 μm (control) were
diluted in buffer, serum and plasma, and their size distributions
were analyzed by fSPT and nanoparticle tracking analysis
(NTA). In a separate experiment, IgG and HSA, fluorescently
labeled with different dyes, were mixed and subjected to heat
stress. The stressed sample was analyzed by fSPT using a dual
color mode and by NTA.
Results The accuracy and precision of fSPT proved to be
comparable to NTA. fSPT was able to successfully measure all
the samples in buffer, serum and plasma. The average size of
the cross-linked protein aggregates showed a slight increase in
biological fluids. Moreover, fSPT analysis showed that a
significant proportion of the aggregates formed by subjecting
an IgG/HSA mixture to heat stress were composed of both
proteins.
Conclusion fSPT is a powerful technique for the characteriza-
tion of submicron protein aggregates in biological fluids and
complex formulations.
KEY WORDS fluorescence single particle tracking . HSA .
IgG . protein aggregates . serum and plasma
INTRODUCTION
Over the past few decades, therapeutic proteins have
become established as a major drug class for the pharma-
ceutical industry. A major challenge in commercializing
proteins as drug candidates is their inherent physical and
chemical instability. Of the numerous degradation path-
ways, protein aggregation is a particular cause for concern
(1,2). It is believed that protein aggregates may have the
propensity in vivo to trigger an antibody response against the
monomeric form of that protein, also known as unwanted
immunogenicity (1,3). The presence of antibodies against a
therapeutic protein can have serious clinical consequences,
such as loss of therapeutic efficacy or even the neutraliza-
tion of the equivalent endogenous protein (4). Therefore,
determination of the amount and type of aggregates
necessary to allegedly trigger such immune reactions is of
major importance both for pharmaceutical companies and
regulatory agencies. With regard to their size, protein-
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containing samples can be very heterogeneous, and individual
aggregates can range in diameter from a few nanometers to
several micrometers or larger (2,5,6).
A number of characterization tools are available for
determining the size of protein aggregates, e.g. size exclusion
chromatography and asymmetrical flow field-flow fraction-
ation combined with UV and light scattering detectors,
dynamic light scattering (DLS) and nanoparticle tracking
analysis (NTA), analytical ultracentrifugation, light obscu-
ration particle counting and micro flow imaging (7–11). A
major limitation of most of these techniques is that it is very
difficult, if not impossible, to use them for analyzing
therapeutic proteins or their aggregates in biological media.
In fact, very little is known about the fate of protein
pharmaceuticals following administration to a patient. To
address this problem, we set out to identify a new strategy
and analytical tool that would allow us to characterize
aggregates of a specific protein in the presence of serum or
plasma.
Very recently, fluorescence Single Particle Tracking
(fSPT) was suggested as a powerful method to size
submicron matter in undiluted biological fluids (12). Using
fSPT, it was shown that the aggregation of fluorescently
labeled liposomal drug carriers can be followed in real time
in undiluted whole blood. In the present work, we have
evaluated the potential of the fSPT technique to detect and
determine the size of submicron protein aggregates in
serum and plasma. To this end, we have covalently labeled
the proteins of interest with a fluorescent probe. This
strategy has previously been applied for the characteriza-
tion of a specific protein interaction in human serum using
analytical ultracentrifugation in an instrument modified to
incorporate a fluorescence detection system (13). The
authors demonstrated that the fluorescence probe did not
affect either the characteristics or the potency of the
protein. The same labeling strategy may also be used to
characterize the aggregates of therapeutic proteins in
complex formulations containing, for example, high
amounts of stabilizing proteins, such as human serum
albumin (HSA).
In this work, a monoclonal antibody (MAb) was fluo-
rescently labeled without affecting its aggregation profile.
Submicron MAb aggregates were generated by applying
stress and were successfully analyzed in biological fluids and
in a formulation containing a large amount of HSA.
MATERIAL AND METHODS
Diluents
The formulation buffer used to prepare the polystyrene
beads and proteins contained 10 mM sodium citrate
(Merck, Darmstadt, Germany), 5% (w/v) sucrose (Sigma-
Aldrich, Buchs, Switzerland), pH 6.0. The formulation
buffer was filtered using a 0.22-μm PES low binding
syringe-driven filter unit (Millex™ GP, Millipore, Ireland).
Human serum and plasma were collected from three
healthy volunteers free of medications. Serum was collected
in Vacutainer SST tubes, and plasma was collected in
Vacutainer heparin tubes (Becton Dickinson, Franklin
Lakes, USA). The plasma samples were centrifuged for
2 min at 2,000 rpm with a Sigma 1-15 centrifuge
(Osterode, Germany) mainly to spin down the red blood
cells. The serum samples were centrifuged for 15 min at
3,000 rpm in a Beckman Coulter Alegra X-12 centrifuge
(Brea, USA) to remove all the blood cells and clotting
factors. The serum and plasma samples were stored at 4°C
for a maximum period of 48 h before being used for
measurements. The viscosities of the buffer, serum and
plasma were measured in an AR-G2 rheometer from TA
Instruments (New Castle, USA) at 37°C. The average
values used for sizing calculations are 0.80 cP, 1.29 cP and
1.30 cP for buffer, serum and plasma, respectively.
Preparation of Fluorescent Polystyrene Beads
Polystyrene FluoSpheres carboxylate-modified micro-
spheres with a nominal size of 0.1 μm, yellow-green
fluorescent (excitation 505 nm/emission 515 nm), were
purchased from Invitrogen (Merelbeke, Belgium) and
covalently linked with methoxy-polyethylene glycol-amine
(m-PEG-amine) (5000 Da, Creative PEGWorks, Winston
Salem, U.S.A.) polymer chains using a method adapted
from Suh et al. in order to minimize interactions with serum
components (14). The fluorescent PEGylated beads were
separately diluted with formulation buffer, serum and
plasma until the concentration was acceptable for either
NTA or fSPT measurements, i.e. 1:5,000 volume-based
dilution for NTA measurements and 1:1,000 volume-based
dilution for fSPT measurements.
Preparation of Alexa Fluor-Labeled IgG
Alexa Fluor 488, Alexa Fluor 546 and Alexa Fluor 594
carboxylic acid, N-hydroxysuccinimide esters were
obtained from Invitrogen (Merelbeke, Belgium). IgG
and HSA labeling was performed according to the
manufacturer’s instructions. In brief, a recombinant
human MAb of the IgG1 subclass (11) was prepared at a
concentration of 10 mg/ml in 100 mM sodium phosphate
(Fluka, Sigma-Aldrich, Buchs, Switzerland) pH 7.4. To
this was added a solution of dye in DMSO (10 mg/ml) to
give a molar ratio of 4:1 (dye:protein). The same
procedure was followed for HSA. A pH of 7.4 was chosen
in order to achieve selective labeling of the amine termini.
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The samples were mixed and left for 1 h at room
temperature. The conjugates were purified by passing
the samples through disposable PD10 desalting columns
(GE Healthcare, Uppsala, Sweden) packed with Sephadex
G25 medium that had been equilibrated with phosphate-
buffered saline (PBS). Finally, the samples were dialyzed
using a Float-A-Lyzer® G2 (Spectrum, Rancho Dominguez,
USA) with a 100 kDa molecular weight cut-off mem-
brane to remove excess dye and to exchange the buffer
from PBS back to the original formulation buffer (see
Diluents subsection). The final labeling ratio achieved was
about four Alexa Fluor 546 labels per IgG, about two
Alexa Fluor 594 labels per IgG and about two Alexa Fluor
488 labels per HSA, according to the formula suggested
by Invitrogen:
nDye
nProtein
¼ Amax
"Dye  cProtein  l
where nDye is the moles of dye, nProtein is the moles of
protein, Amax is the measured absorbance at the dye’s
absorption maximum, εdye is the molar extinction coeffi-
cient of the dye at its absorption maximum, cProtein is the
molar protein concentration (determined by absorbance at
280 and corrected for the presence of dye, according to
the correction formulas given by the dye supplier) and l is
the path length.
Preparation of Fluorescently Labeled Protein
Aggregates
Covalent aggregates of Alexa Fluor 546-labeled IgG
(A546 IgG) were prepared by using glutaraldehyde
(Sigma-Aldrich, Steinheim, Germany) as a cross-linker.
The aggregates were obtained by incubating 0.5 mg/ml
of A546 IgG with 0.2% (v/v) of glutaraldehyde for 2 min
at room temperature. The cross-linking reaction was
terminated by adding sodium borohydride (Sigma-
Aldrich, Steinheim, Germany) at a final concentration
of 0.008% (w/v). This reaction was then allowed to
proceed for 24 h at room temperature. The sample was
diluted 250-fold with the formulation buffer, serum or
plasma before the fSPT analysis and 5-fold before the
NTA measurements.
For the preparation of fluorescently labeled protein
aggregates in a complex formulation, Alexa Fluor 594-
labeled IgG (A594 IgG) was prepared at a concentration of
0.5 mg/ml in formulation buffer (see Diluents subsection)
containing Alexa Fluor 488-labeled HSA (A488 HSA) at a
concentration of 3.2 mg/ml. The sample was placed in a
1.5-ml reaction tube (Eppendorf, Hamburg, Germany) and
incubated for 12 min at 74°C in a VWR Digital Heat Block
(VWR, West Chester, USA). The sample was diluted
1,000-fold with the formulation buffer before the fSPT
and 50-fold before the NTA measurements.
Nanoparticle Tracking Analysis (NTA)
NTA measurements were performed essentially as described
before with a NanoSight LM20 (NanoSight, Amesbury,
United Kingdom), equipped with a sample chamber with a
640-nm laser and a Viton fluoroelastomer O-ring (11). The
samples were injected in the sample chamber with sterile
syringes (BD Discardit II, New Jersey, USA), and all
measurements were performed at 37°C. The software used
for capturing and analyzing the data was the NTA 2.0 Build
127. The samples were measured for 40 s with manual
shutter and gain adjustments. Three measurements of the
same sample were performed for the polystyrene beads and
six measurements for the protein aggregates. The standard
deviations of the mean size values were calculated from the
values obtained in each measurement.
Light Obscuration (LO)
LO measurements were performed on a PAMAS SVSS
system (PAMAS GmbH, Rutesheim, Germany) equipped
with a HCB-LD-25/25 sensor and a 1 ml syringe. Each
sample was measured three times, with each measurement
consisting of a pre-run volume of 0.3 ml followed by three
runs of 0.2 ml at a flow rate of 10 ml/min. The
measurement settings differ significantly from the United
States Pharmacopeia (USP) method, but they were chosen
in order to reduce sample volume, since it has been shown
that small sampling volumes are appropriate for quantify-
ing size and levels of subvisible particles at the amounts
typically present in protein therapeutics (15). The samples
were diluted 100-fold with the formulation buffer before
the measurements in order to keep the particle counts
below the upper count limit of the device.
Fluorescence Single Particle Tracking (fSPT)
The fSPT technique was recently described in detail
elsewhere (12). In short, widefield laser illumination was
provided to an inverted epi-fluorescence microscope
(Nikon TE2000E, NIKON BELUX, Brussels, Belgium)
for excitation of the fluorescently labeled sample. The
fSPT setup was equipped with three solid state lasers: a
100 mW Calypso 491 nm (Cobolt, Solna, Sweden), a
75 mW Jive 561 nm (Cobolt) and a IQ1C 30 mW 636 nm
(Power Technology, Little Rock, AR). Using a fast and
sensitive electron-multiplying CCD camera (Cascade
II:512; Roper Scientific, Tucson, AZ), videos were
acquired (Nikon Elements R imaging software) of the
fluorescently labeled protein aggregates diffusing in the
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medium (formulation buffer, serum, or plasma). A Nikon
Plan Apochromat 100× NA1.4 oil immersion objective
lens was used for imaging.
Using custom-built software, diffusional motion trajectories
were calculated for individual protein aggregates from the
fSPT videos. Since the diffusion coefficient for each trajectory
could be calculated, a distribution of diffusion coefficients was
obtained by analyzing a large number of trajectories. A
maximum entropy deconvolution algorithm was used to
reduce statistical broadening and sampling noise in the
distribution of diffusion coefficients. Finally, this distribution
of diffusion coefficients was converted to a size distribution
using the Stokes-Einstein equation for spherical particles:
d ¼ kT
3Dph
where d is the particle diameter, k the Boltzmann constant, T
the absolute temperature, η the dynamic viscosity of the
solution and D the diffusion coefficient.
Each measurement consisted of the recording and
analysis of ten videos of the same sample for the polystyrene
beads and 20 videos for the protein aggregates. Each video
was recorded for only 5 s in order to minimize photo-
bleaching. The standard deviations of the mean size values
were calculated from the values obtained in each video.
The upper and lower size and concentration limits of
fSPT are hard to specify, since they are dependent on
several complex analytical factors. The lower size limit for
detecting a particle depends on the ratio between the
background intensity and the number of photons that can
be collected from that particle, which in turn is dependent
on the brightness of the fluorescent label, laser intensity and
illumination time. Nevertheless, in our experiments, par-
ticles as small as 50 nm could be successfully measured. The
upper size limit is mostly related to the particle density and
fluid viscosity in such a way that particle sedimentation
becomes the limiting factor. In a general way, an upper size
limit of about 1000 nm can be set for fSTP measurements.
With this technique, the upper limit of particle concen-
tration is dictated by the optical resolution and the tracking
algorithm, resulting in a maximum useful particle concen-
tration that is typically in the nanomolar range (12).
Theoretically, there is no lower limit of particle concentra-
tion, since the size is calculated for individual particles.
However, it is clear that there should be a sufficient number
of particles in the system to obtain good statistics within a
reasonable time period.
Colocalization Analysis
In order to verify whether IgG and HSA can form mixed
aggregates, A594 IgG (red fluorescent) and A488 HSA
(green fluorescent) were combined, and the mixture was
subsequently subjected to heat stress (12 min at 74°C). The
resulting aggregate-containing solution was then analyzed
by dual color fSPT.
Dual color is an fSPT mode in which videos can be
recorded simultaneously in two different spectral ranges
(green and red in this case), enabling separate video analysis
and the detection of particle colocalization between both
videos. Since aggregates are seen in fSPT videos as separate
objects (spots of light), an object-based algorithm was
employed for quantification. For each frame of the movie,
all green and red objects were identified by image
processing (for details, see Braeckmans et al.) (16). For each
object, the contour and centre position were determined. A
green object was considered colocalized with a red object if
its center position fell within the contour of the red object.
Vice versa, a red object was considered colocalized with a
green object if its center position fell within the contour of
the green object. By performing this analysis for all frames
of a movie, the percentage of mixed aggregates relative to
the pure IgG or HSA aggregates could be estimated.
RESULTS AND DISCUSSION
Fluorescent Polystyrene Beads in Biological Fluids
In line with previous studies, we first verified that fSPT
can accurately detect and size submicron particles in
biological fluids (12). PEGylated standard fluorescent
polystyrene beads of 0.1 μm nominal size were separately
diluted in buffer, serum and plasma, and the size
distributions were then measured by fSPT (Fig. 1). The
samples in buffer were also analyzed by NTA as a control,
since both sizing techniques are based on the same
principle of tracking individual particles and calculating
the particle hydrodynamic size from the measured
diffusion coefficient. However, the standard NTA instru-
ment, as described by Filipe et al. (11), relies on light
scattered by the particles and, therefore, cannot be used
for biological media like serum or plasma, which contain a
variety of light scattering components.
The size distributions obtained by fSPT and NTA for
the PEGylated beads in buffer are comparable, confirming
the accuracy of fSPT to size nanoparticles. The mean size
given by NTA was 129±7 nm, while the mean sizes given
by fSPT were 139±10 nm in buffer, 143±7 nm in serum
and 142±8 nm in plasma. The source of the small
difference between the means given by the two techniques
in buffer is unknown, but may have to do with the
contribution of small impurities (between 50 and 120 nm)
associated with the PEGylation process. Such impurities
would decrease the NTA mean but cannot be detected by
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fSPT, since they would not be fluorescent. In any case, the
mean values are within the standard deviations obtained for
both techniques. These standard deviations of the means
are small and very similar between the two techniques,
confirming the precision of fSPT.
The fSPT size distributions are also very similar in each
of the media, indicating that the beads do not aggregate in
biological fluids and that these fluids do not interfere with
the fluorescence properties of the beads. Moreover, it can
be concluded that the clotting factors, which are present in
plasma and not in serum, have no major effect on the size
distribution of the beads. These results demonstrate the
potential of this technique to measure the size distribution
of nanoparticles in biological fluids.
Effect of Labeling on Aggregation Profile
With the aim of evaluating the effect of the fluorescent label
on the aggregation profile of this specific IgG, a comparative
aggregation study between A546-labeled and unlabeled IgG
was performed. The samples were stressed by glutaraldehyde
cross-linking under the same conditions, and the aggregates
were analyzed byNTA and LO (Fig. 2). Combined, these two
techniques focus on the size range covered by fSPT
(submicron range) and on the size range that can interfere
with fSPT measurements (micron range).
The NTA size distribution of the labeled IgG samples is
very similar to that of the unlabeled one. The height difference
between the two peaks is within the variations inherent to the
stress method itself and therefore should not be taken into
account. The LO measurements also show a similar size
distribution and particle count per size bin between the two
samples. These results lead to the conclusion that this
fluorescent label does not have a major impact on the
aggregation profile in the subvisible and submicron range of
this specific IgG with this particular stress method.
These findings should not be generalized for other
proteins, other fluorescent labels or other stress methods.
During optimization studies, we verified that some fluores-
cent dyes may significantly change the aggregation profile
of some proteins in certain given conditions (data not
shown). Therefore, a case-by-case approach should be
followed to evaluate the effect of a fluorescent label on a
certain protein’s stability.
Covalent A546 IgG Aggregates in Biological Fluids
In order to evaluate the analytical performance of fSPT for
protein aggregates in biological fluids, covalent submicron
A546 IgG aggregates were analyzed in buffer, serum and
plasma (Fig. 3). Glutaraldehyde cross-linked covalent aggre-
gates were used, since they cannot be dissociated and can be
considered to be stable aggregates. Unstressed A546 IgG was
also analyzed by fSPT in each of the media and was shown
not to contain aggregates. As an additional control, the
sample diluted in buffer was also measured by NTA.
Fig. 1 Size distribution from fSPT and NTA measurements of PEGylated
fluorescent polystyrene beads in buffer, serum and plasma.
Fig. 2 Size distribution from NTA and LO measurements in buffer of A546 IgG and unlabeled IgG aggregates induced by glutaraldehyde cross-linking.
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The size average of the A546 IgG aggregates in buffer
measured with NTA was 215±38 nm and with fSPT 198±
36 nm. The difference observed in peak width between the
NTA and fSPT size distributions in buffer can be attributed
to a difference in the size analysis algorithm. In the fSPT
sizing method used here, the raw size distribution as
measured directly from the particle trajectories is refined
by a maximum entropy deconvolution step that filters out
statistical broadening and sampling noise so as to not over-
interpret features in the distribution that are not statistically
warranted by the data (12). Although a similar function is
available in the NTA software (model curve fitting), we chose
to use the log-normal fit of the data for this sample, given
that according to the manufacturer, this function should
only be used for either very monodisperse or clearly
bimodal samples. Another factor that can contribute to
the difference in peak width is the difference in optimal
dilutions (50-fold) required for measurements with each
technique, since higher dilutions may affect the aggregate
size distribution (7).
These glutaraldehyde cross-linked aggregates showed an
increase in their mean size in serum and plasma compared
to buffer (198±36 nm, 265±38 nm and 245±34 nm in
buffer, serum and plasma, respectively). This size increase
could be due to self-association of the aggregates or to
interactions between the aggregates and other serum and
plasma components, a phenomenon normally described as
opsonization (17). In general, opsonization is the adsorption
of plasma components (i.e. opsonins) onto the surface of a
foreign particle to render it more susceptible to phagocy-
tosis. Opsonins include mainly immunoglobulins, blood
clotting factors and components of the complement system
(18,19). Given that the IgG used in this work is humanized
and that IgG is one of the most abundant classes of proteins
circulating in blood, one would not expect it to be
opsonized. However, protein cross-linking with glutaralde-
hyde leads to a high amount of intermolecular and
intramolecular cross-links, which normally lead to confor-
mational changes (20–22). Consequently, since opsonins
bind to nanoparticles mainly via hydrophobic interactions,
it is possible that these unnatural aggregates of conforma-
tionally changed IgG may lead to some opsonization (23).
Given that the size distribution of these aggregates is
relatively the same in serum and in plasma, it is possible to
conclude that the presence of clotting factors has little
impact on the hypothetical opsonization, since they do not
have a major effect on the size average of these aggregates.
A594 IgG Aggregates Formulated with A488 HSA
Over the last few decades, the need to stabilize therapeutic
proteins progressively led to rather complex formulations
containing sugars, surfactants, amino acids and even other
proteins. However, such intricate environments often make
the selective characterization of the therapeutic protein very
difficult. For example, several therapeutic protein formula-
tions contain high concentrations of HSA, which is known
to act as a general stabilizer for liquid and lyophilized
protein formulations by effectively inhibiting protein sur-
face adsorption (24,25). Unfortunately, with most protein
characterization tools, it is virtually impossible to distin-
guish between the excipient HSA and the therapeutic
protein without prior separation. When considering protein
aggregates, the situation becomes even more complex, as
both the protein drug and HSA may form separate or
mixed aggregates.
This section aims to show the potential of fSPT for the
selective characterization of protein aggregates in formula-
tions containing high amounts of HSA. For this purpose,
A594 IgG was mixed with A488 HSA at an IgG:HSA
concentration ratio of 1:6 (w/w); the mixture was heated in
order to stimulate the formation of aggregates with
diameters of the order of a hundred nanometers (monitored
by fSPT). The sample was then analyzed by fSPT using dual
color imaging (Fig. 4), whereby Alexa Fluor 488 and Alexa
Fig. 3 Size distribution from fSPTand NTA measurements of glutaraldehyde
cross-linked A546 IgG in buffer, serum and plasma.
Fig. 4 Size distribution from fSPT and NTA measurements of a heat-
stressed mixture of A594 IgG and A488 HSA in buffer.
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Fluor 594-labeled aggregates could be tracked simultaneously
to examine whether HSA and IgG form mixed aggregates or
not. The overall aggregate size was also measured by NTA,
although it cannot distinguish between IgG aggregates, HSA
aggregates or mixed aggregates (Fig. 4).
The average size of the aggregates determined by NTA
was 152 nm. By fSPT, the average size of the IgG-
containing and HSA-containing aggregates was 161 nm
and 122 nm, respectively (Table I). These results suggest
that either the aggregates of both proteins have coincidently
the same size range or that these aggregates are composed
of both proteins. In order to clarify this uncertainty, the
videos from both IgG (red fluorescence) and HSA (green
fluorescence) channels were aligned, and an object-based
colocalization was calculated. A representative fSPT video
frame is shown on Fig. 5, wherein colocalization is clearly
visible (see also Supplementary Material for complete
overlaid video). The results show that the IgG-containing
aggregates colocalize significantly with the HSA-containing
aggregates. About 70±9% of the aggregates tracked in the
IgG channel were found to be colocalized with HSA-
containing aggregates, while only about 36±4% of the
aggregates tracked in the HSA channel colocalized with
IgG-containing aggregates. The amount of aggregates
tracked in the HSA channel was approximately twice the
amount of aggregates tracked in the IgG channel. This
indicates that there were more HSA-containing aggregates
than IgG-containing aggregates, and this explains the low
colocalization observed for the aggregates in the HSA
channel. The fact that there were more HSA aggregates is
not surprising considering the IgG:HSA concentration ratio
of 1:6 (w/w). An example of this occurrence can be seen in
Fig. 5, where two out of five HSA aggregates do not
colocalize with IgG aggregates.
Previous studies have already suggested the interaction
between therapeutic proteins and HSA to form mixed
aggregates in solution, mainly by enzyme-linked immuno-
sorbent assays (26,27). In the present study, using dual color
fSPT, we were for the first time able to visualize and get a
clear glimpse at the aggregation profile of therapeutic
proteins in formulations containing HSA. Here, we have
clearly demonstrated that under conditions of heat stress,
HSA can form mixed aggregates with the therapeutic
protein: in this case, IgG. Given that heat stress induces
protein denaturation and consequently exposure of hydro-
phobic regions, it is likely that HSA starts to bind to the
partially denatured intermediates of the therapeutic protein
and ends up involved in the overall aggregation process
(25,28). In fact, the same heat stress was applied to the
A594 IgG in a formulation without A488 HSA, and it
resulted in a much higher amount of IgG aggregates with a
higher size average, confirming the stabilizing properties of
HSA in solution (data not shown).
It should be noted that control experiments in buffer
with only one of the two proteins labeled indicated that the
labeling of HSA or IgG did not change the size distribution.
However, labeling of HSA (but not IgG) substantially
reduced the amount of submicron aggregates (as measured
by NTA), even though the amount of micron-sized
aggregates (as measured by LO) remained approximately
the same (data not shown). This may be due to the
hydrophobic nature of the label and/or the (random) HSA
labeling procedure. Further studies with other labels or
different, site-specific labeling strategies should be done in
order to understand and avoid this problem.
Table I Mean Size from NTA and fSPT Measurements of a Heat-
Stressed Mixture of A594 IgG and A488 HSA in Buffer
fSPT NTA
Mean (nm) Colocalization (%) Mean (nm)
Scattering - - 152
A488 HSA Channel 122 36±4 -
A594 IgG Channel 161 70±9 -
Fig. 5 A video frame containing aggregates captured in the IgG and HSA channels using the dual color mode of fSPT, with the corresponding overlay image.
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CONCLUDING REMARKS
In this work, we evaluated the potential of fSPT for the
characterization of protein aggregates in biological fluids and
HSA-containing formulations. fSPT gave comparable size
distributions to NTA for aggregates and particles in buffer and
has the added advantage that it can also be applied to look at
samples in serum and plasma. It seems that some serum
components adsorb to the beads and protein aggregates once
these come into contact with biological fluids. fSPT has also
been shown to be suitable for selectively analyzing protein
aggregates in complex formulations, such as those containing
HSA. Using dual color fSPT, it was possible to verify that most
of the IgG aggregates created by heat stress in an HSA-
containing formulation were in fact composed of a mixture
of IgG and HSA.
The requirement for prior labeling of the protein of interest
with a fluorescent probe may be seen as a drawback of this
technique. However, if it can be proven that the stability and
aggregation profile of the proteins remain unaltered after the
labeling, the potential of this technique to reveal the fate of
protein aggregates in biological fluids is evident. This paves
the way for several research areas, such as formulation and
immunogenicity studies, where it is important to know if a
certain therapeutic protein aggregates once injected into the
bloodstream or if certain types of aggregates disappear or
change their size in biological fluids.
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